Mineralys Therapeutics Inc
MLYS13.420USD
-0.245-1.79%
取引時間 （ET）15分遅れの株価
870.64M時価総額
損失額直近12ヶ月PER
詳細情報 Mineralys Therapeutics Inc 企業名
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone. The Company’s product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is initially developing for the treatment of patients with uncontrolled hypertension (uHTN). Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. The Company completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uHTN. In addition to hypertension, the Company intends to develop lorundrostat for the treatment of chronic kidney disease (CKD).
企業情報
企業コードMLYS
会社名Mineralys Therapeutics Inc
上場日Feb 10, 2023
最高経営責任者「CEO」Mr. Jon Congleton
従業員数51
証券種類Ordinary Share
決算期末Feb 10
本社所在地150 N. Radnor Chester Road
都市RADNOR
証券取引所NASDAQ Global Select Consolidated
国United States of America
郵便番号19087
電話番号18883786240
ウェブサイトhttps://mineralystx.com/
企業コードMLYS
上場日Feb 10, 2023
最高経営責任者「CEO」Mr. Jon Congleton
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Jon Congleton
Mr. Jon Congleton
Chief Executive Officer, Director
Chief Executive Officer, Director
678.62K
-2.29%
Mr. Adam Scott Levy
Mr. Adam Scott Levy
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
62.70K
-57.38%
Mr. Glenn P. Sblendorio
Mr. Glenn P. Sblendorio
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Alexander M. Gold, M.D.
Mr. Alexander M. Gold, M.D.
Independent Director
Independent Director
--
--
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Derek Dirocco, Ph.D.
Dr. Derek Dirocco, Ph.D.
Independent Director
Independent Director
--
--
Dr. David M. Rodman, M.D.
Dr. David M. Rodman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Daphne Karydas
Ms. Daphne Karydas
Independent Director
Independent Director
--
--
Dr. Brian Taylor (Bt) Slingsby, M.D., Ph.D.
Dr. Brian Taylor (Bt) Slingsby, M.D., Ph.D.
Founder, Independent Director
Founder, Independent Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Jon Congleton
Mr. Jon Congleton
Chief Executive Officer, Director
Chief Executive Officer, Director
678.62K
-2.29%
Mr. Adam Scott Levy
Mr. Adam Scott Levy
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
62.70K
-57.38%
Mr. Glenn P. Sblendorio
Mr. Glenn P. Sblendorio
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Alexander M. Gold, M.D.
Mr. Alexander M. Gold, M.D.
Independent Director
Independent Director
--
--
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Derek Dirocco, Ph.D.
Dr. Derek Dirocco, Ph.D.
Independent Director
Independent Director
--
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Sat, Jul 19
更新時刻: Sat, Jul 19
株主統計
種類
株主統計
株主統計
比率
Catalys Pacific, LLC
13.26%
RA Capital Management, LP
9.43%
Samsara BioCapital, LLC
8.71%
SR One Capital Management, LP
4.80%
Capital Research Global Investors
4.45%
Other
59.35%
株主統計
株主統計
比率
Catalys Pacific, LLC
13.26%
RA Capital Management, LP
9.43%
Samsara BioCapital, LLC
8.71%
SR One Capital Management, LP
4.80%
Capital Research Global Investors
4.45%
Other
59.35%
種類
株主統計
比率
Investment Advisor
38.81%
Hedge Fund
23.09%
Venture Capital
22.96%
Investment Advisor/Hedge Fund
16.44%
Individual Investor
1.40%
Research Firm
1.10%
Pension Fund
0.67%
Private Equity
0.61%
Bank and Trust
0.09%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
285
69.20M
106.19%
+10.20M
2025Q1
278
68.91M
105.92%
+7.50M
2024Q4
230
53.93M
108.22%
-5.12M
2024Q3
214
51.53M
103.61%
-6.38M
2024Q2
197
51.29M
104.21%
-4.08M
2024Q1
188
49.20M
100.04%
-4.93M
2023Q4
172
42.00M
101.88%
-1.03M
2023Q3
140
43.25M
105.60%
+16.34M
2023Q2
116
41.91M
102.57%
+17.25M
2023Q1
99
41.30M
101.10%
+30.53M
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Catalys Pacific, LLC
8.64M
13.26%
--
--
Mar 31, 2025
RA Capital Management, LP
6.15M
9.43%
+1.30M
+26.72%
Mar 31, 2025
Samsara BioCapital, LLC
5.67M
8.71%
+600.00K
+11.82%
Mar 31, 2025
SR One Capital Management, LP
3.13M
4.8%
+1.11M
+55.09%
Mar 31, 2025
TCG Crossover Management, LLC
2.47M
3.79%
--
--
Mar 31, 2025
Integral Health Asset Management, LLC
2.30M
3.53%
+1.43M
+162.86%
Mar 31, 2025
HBM Partners AG
2.25M
3.45%
--
--
Sep 30, 2024
BlackRock Institutional Trust Company, N.A.
2.20M
3.38%
+266.41K
+13.75%
Mar 31, 2025
Caligan Partners, LP
2.15M
3.3%
+1.14M
+112.60%
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Sat, Aug 2
更新時刻: Sat, Aug 2
銘柄名
比率
Virtus LifeSci Biotech Clinical Trials ETF
0.82%
SPDR S&P Biotech ETF
0.2%
iShares Micro-Cap ETF
0.12%
Direxion Daily S&P Biotech Bull 3X Shares
0.11%
ProShares Ultra Nasdaq Biotechnology
0.1%
Invesco Nasdaq Biotechnology ETF
0.1%
iShares Biotechnology ETF
0.06%
iShares Russell 2000 Growth ETF
0.04%
Invesco Russell 2000 Dynamic Multifactor ETF
0.03%
ProShares UltraPro Russell2000
0.02%
詳細を見る
Virtus LifeSci Biotech Clinical Trials ETF
比率0.82%
SPDR S&P Biotech ETF
比率0.2%
iShares Micro-Cap ETF
比率0.12%
Direxion Daily S&P Biotech Bull 3X Shares
比率0.11%
ProShares Ultra Nasdaq Biotechnology
比率0.1%
Invesco Nasdaq Biotechnology ETF
比率0.1%
iShares Biotechnology ETF
比率0.06%
iShares Russell 2000 Growth ETF
比率0.04%
Invesco Russell 2000 Dynamic Multifactor ETF
比率0.03%
ProShares UltraPro Russell2000
比率0.02%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
